High Valuations Sideline Sanofi From The M&A Game…For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi CEO Chris Viehbacher said the company is focusing mainly on bolt-on acquisitions because valuations for targets have ballooned so significantly. Inversion deals are further inflating assets, he said.
You may also be interested in...
Emerging Markets Earnings Roundup: Amgen, Sanofi (Part 14)
Amgen is fairly quiet on international in the second quarter, but Sanofi says it is back on track in Brazil and emerging markets generally.
Sanofi Investing €700 Million Ahead Of Launches
Sanofi is ramping up for several product launches in the next 12 months, including a next-generation basal insulin Toujeo, Lemtrada for multiple sclerosis, Cerdelga for Gaucher’s disease and Praluent for high cholesterol.
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.